Sangamo Therapeutics, Inc. (SGMO) Stock Analysis

Sangamo Therapeutics, Inc. (SGMO) Healthcare & Pipeline Overview

Sangamo Therapeutics, Inc. pioneers genomic medicines using gene therapy, cell therapy, genome editing, and regulation technologies. With a focus on zinc finger protein (ZFP) technology, they are developing treatments for hemophilia A, Fabry disease, and sickle cell disease, positioning them as an innovator in the biotechnology sector.

What Is the Investment Thesis for SGMO?

Sangamo Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's diverse pipeline of genomic medicines, particularly SB-525 in Phase III trials for hemophilia A, offers significant potential upside. Successful clinical trial outcomes and subsequent regulatory approvals could drive substantial revenue growth. However, the company's negative profit margin of -310.8% highlights its reliance on partnerships and future product revenue. Key catalysts include clinical trial readouts for ST-920 and SAR445136. The company's beta of 1.50 indicates higher volatility compared to the market. Investment hinges on the successful execution of clinical programs and strategic collaborations.

Based on FMP financials and quantitative analysis

SGMO Key Highlights

Market capitalization of $30.7M reflects the company's current valuation and growth potential in the genomic medicine space.

• Gross margin of 80.8% indicates strong potential profitability upon commercialization of successful therapies.
• Profit margin of -310.8% highlights the significant R&D expenses associated with clinical-stage biotechnology companies.
• SB-525 in Phase III AFFINE clinical trial for hemophilia A represents a near-term value driver.
• Collaborative partnerships with Biogen, Pfizer, and Sanofi provide financial support and validation of Sangamo's technology.

Who Are SGMO's Competitors?

SGMO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SGMO's Key Strengths?

Proprietary ZFP technology platform.

• Diverse pipeline of genomic medicines.
• Strategic partnerships with leading pharmaceutical companies.
• Strong intellectual property portfolio.

What Are SGMO's Weaknesses?

Negative profit margin and reliance on external funding.

• Clinical trial risks and regulatory hurdles.
• Competition from other gene editing companies.
• Limited commercialized products.

What Could Drive SGMO Stock Higher?

Data readout from Phase III AFFINE clinical trial for SB-525 in Hemophilia A.

• Data readout from Phase I/II STAAR clinical trials for ST-920 in Fabry disease.
• Advancement of SAR445136 in Phase I/II PRECIZN-1 clinical trials for sickle cell disease.
• Continued progress in strategic partnerships with Biogen, Pfizer, and Sanofi.

What Are the Key Risks for SGMO?

Listing risk — at $0.074 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays could negatively impact the company's pipeline and valuation.
• Regulatory setbacks or rejection of marketing applications could hinder commercialization efforts.
• Competition from other gene editing companies could erode market share.
• Dependence on strategic partnerships for funding and expertise poses a risk if collaborations are terminated or unsuccessful.

What Are the Growth Opportunities for SGMO?

• Advancement of SB-525 for Hemophilia A: The Phase III AFFINE clinical trial for SB-525 represents a significant near-term growth opportunity. Hemophilia A is a large market with unmet medical needs, and positive trial results could lead to regulatory approval and commercialization, potentially generating substantial revenue. The global hemophilia A market is projected to reach $15 billion by 2028.
• Development of ST-920 for Fabry Disease: ST-920, a gene therapy in Phase I/II clinical trials for Fabry disease, offers another growth avenue. Fabry disease is a rare genetic disorder with limited treatment options. Successful development and commercialization of ST-920 could capture a significant share of the Fabry disease market, estimated at $2 billion.
• Expansion of Cell Therapy Programs: Sangamo's cell therapy programs, including SAR445136 for sickle cell disease and KITE-037 for cancer, represent long-term growth opportunities. Cell therapy is a rapidly growing field with the potential to revolutionize the treatment of various diseases. The global cell therapy market is projected to reach $80 billion by 2030.
• Strategic Partnerships: Sangamo's collaborative partnerships with Biogen, Pfizer, and Sanofi provide access to funding, expertise, and resources, accelerating the development and commercialization of its genomic medicines. These partnerships also validate Sangamo's technology and enhance its credibility in the industry. Continued strategic alliances will be crucial for future growth.
• Expansion into New Therapeutic Areas: Sangamo's pipeline includes programs targeting tauopathies and synucleinopathies, including Parkinson's disease. These programs represent opportunities to expand into new therapeutic areas with significant unmet medical needs. Success in these areas could diversify Sangamo's revenue streams and drive long-term growth. The market for Parkinson's disease treatment is projected to reach $6 billion by 2027.

What Threats Does SGMO Face?

• Clinical trial failures and regulatory setbacks.
• Competition from established pharmaceutical companies.
• Patent disputes and intellectual property challenges.
• Changes in healthcare regulations and reimbursement policies.

What Are SGMO's Competitive Advantages?

• Proprietary zinc finger protein (ZFP) technology platform.
• Extensive intellectual property portfolio in genomic medicine.
• Established partnerships with leading pharmaceutical companies.
• Clinical-stage pipeline of genomic medicines targeting unmet medical needs.

What Does SGMO Do?

Sangamo Therapeutics, Inc., founded in 1995 and headquartered in Brisbane, California, is a clinical-stage biotechnology company dedicated to translating scientific advancements into genomic medicines. The company's core focus lies in developing transformative treatments using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo's pioneering work centers around its zinc finger protein (ZFP) technology, a platform for creating zinc finger nucleases that modify DNA sequences by adding or knocking out specific genes, and ZFP transcription factors that modulate gene expression. Sangamo's pipeline includes several clinical-stage programs. SB-525 is currently in Phase III clinical trials for the treatment of hemophilia A. ST-920, a gene therapy, is in Phase I/II clinical trials for Fabry disease. SAR445136, a cell therapy, is in Phase I/II clinical trials for sickle cell disease. Additionally, Sangamo is developing TX200 for kidney transplant rejection, KITE-037 for cancer, ST-501 for tauopathies, and ST-502 for synucleinopathies, including Parkinson's disease. The company collaborates with industry leaders such as Biogen, Kite Pharma, Pfizer, and Sanofi, leveraging partnerships to advance its research and development efforts. Formerly known as Sangamo BioSciences, Inc., the company rebranded as Sangamo Therapeutics, Inc. in January 2017 to reflect its expanded focus on therapeutic applications of its genomic technologies.

What Products and Services Does SGMO Offer?

• Develop genomic medicines using gene therapy.
• Develop genomic medicines using cell therapy.
• Develop genomic medicines using genome editing.
• Develop genomic medicines using genome regulation.
• Utilize zinc finger protein (ZFP) technology to modify DNA sequences.
• Develop treatments for hemophilia A, Fabry disease, and sickle cell disease.
• Collaborate with pharmaceutical companies to advance research and development.

How Does SGMO Make Money?

• Develops and out-licenses genomic medicine technologies.
• Generates revenue through collaborative partnerships with pharmaceutical companies.
• Aims to generate revenue through commercialization of proprietary therapies.
• Focuses on R&D to expand its pipeline of genomic medicines.

What Industry Does SGMO Operate In?

Sangamo Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the genomic medicine sector. This sector is characterized by high growth potential driven by advancements in gene therapy, cell therapy, and genome editing technologies. The competitive landscape includes companies like CRISPR Therapeutics and Editas Medicine, which are also focused on genome editing.

Who Are SGMO's Key Customers?

• Patients with genetic diseases such as hemophilia A, Fabry disease, and sickle cell disease.
• Pharmaceutical companies seeking to develop and commercialize genomic medicines.
• Research institutions and academic centers.

Over the past six months, Sangamo Therapeutics, Inc. insiders filed 12 SEC Form 4 transactions — 7 sales and 5 purchases. On net that is roughly 4.1M shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

Wall Street analysts project Sangamo Therapeutics, Inc. revenue of about $9.9M for fiscal 2026, with EPS near $-0.30.

Sangamo Therapeutics, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 124.9% below estimates on average.

Sangamo Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Key Financial Metrics

Return on assets is -94.4%, showing how much profit it generates from its asset base. A current ratio of 0.70 means current liabilities exceed short-term assets, a liquidity point worth watching.

Sangamo Therapeutics, Inc. (SGMO) Valuation Context

Valued at $30.7M, SGMO is classified as a micro-cap stock.

SGMO Revenue & Earnings Trend

In Mar 2026, SGMO generated $1.4M in top-line revenue, marking a sequential decrease of 89.9%. The company recorded a net loss of $31.0M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SGMO averaged $-0.10 in diluted EPS.

Company Profile

Sangamo Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Richmond, US. The company is led by CEO Alexander D. Macrae Ch.B. SGMO has traded publicly since 2000.

SGMO Financials

SGMO Latest News

SGMO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources